{
    "clinical_study": {
        "@rank": "109219", 
        "arm_group": {
            "arm_group_label": "Degarelix treated group", 
            "arm_group_type": "Experimental", 
            "description": "240mg degarelix s.c. injection to be administered 7-14 days prior to radical prostatectomy for high/intermediate risk prostate cancer."
        }, 
        "brief_summary": {
            "textblock": "The biological effects of castration on prostate cancers will be studies by administration\n      of degarelix prior to radical prostatectomy.\n\n      The effects will be studied by analysis of gene expression and immunohistochemistry focusing\n      on markers of proliferation and apoptosis of samples taken at the time of radical\n      prostatectomy (7-14 days after administration of degarelix).\n\n      Tumours from patients treated with neo-adjuvant degarelix will be compared with tumours from\n      patients who have not been medically castrated."
        }, 
        "brief_title": "Degarelix Before Radical Prostatectomy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Intermediate/high risk prostate cancer\n\n          -  Patient eligible for and wanting surgery\n\n        Exclusion Criteria:\n\n          -  Inability to consent\n\n          -  Previous thromboembolism/arrhythymias\n\n          -  contraindication to degarelix or surgery"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852864", 
            "org_study_id": "11/H0311/2"
        }, 
        "intervention": {
            "arm_group_label": "Degarelix treated group", 
            "description": "7-14 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.", 
            "intervention_name": "240mg degarelix s.c. injection", 
            "intervention_type": "Drug", 
            "other_name": "medical castration"
        }, 
        "intervention_browse": {
            "mesh_term": "Testosterone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostate cancer", 
            "testosterone", 
            "castration", 
            "degarelix", 
            "proliferation"
        ], 
        "lastchanged_date": "May 9, 2013", 
        "location": {
            "contact": {
                "last_name": "Greg Shaw"
            }, 
            "facility": {
                "address": {
                    "city": "Cambridge", 
                    "country": "United Kingdom", 
                    "state": "Cambridgeshire", 
                    "zip": "CB20QQ"
                }, 
                "name": "Cambridge University Hopital NHS Trust"
            }, 
            "investigator": {
                "last_name": "David Neal, MS FRCS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study of the Early Biological Effects of Testosterone Suppression in Prostate Cancer Using Neoadjuvant Degarelix Prior to Radical Prostatectomy", 
        "overall_contact": {
            "email": "greg.shaw@cruk.cam.ac.uk", 
            "last_name": "Greg Shaw, MBBS MD FRCS", 
            "phone": "01223 331940"
        }, 
        "overall_contact_backup": {
            "email": "marie.corcoran@addenbrookes.nhs.uk", 
            "last_name": "Marie Corcoran", 
            "phone": "01223348441"
        }, 
        "overall_official": {
            "affiliation": "Cambridge University", 
            "last_name": "David Neal, BSc MS FRCS", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United kingdom: MHRA This study is not a CTIMP. MHRA have reviewed protocol and excluded need for further involvement"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "proliferative index defined by immunohistochemistry for ki67", 
            "safety_issue": "No", 
            "time_frame": "at surgery, 7-14 days after administration of degarelix"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852864"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cambridge", 
            "investigator_full_name": "Greg Shaw", 
            "investigator_title": "Clinical Lecturer in Urology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Gene expression levels measured by microarray", 
            "safety_issue": "No", 
            "time_frame": "At surgery 7-14 days after degarelix administration"
        }, 
        "source": "University of Cambridge", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Cambridge", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}